Tuesday 21 July | Poster Exhibition

| Venue: Hall B on the West Exhibition Level | TUPEA057 Prevalence, evolutionary dynamics and transmission pattern of HCV, HIV-1 and HPGV among injecting drug users |
| The Poster Exhibition is open from Monday 20 - Wednesday 22 July from 10:00 to 18:30. | Malaysia |
| Posters will be displayed for the duration of the conference (Monday to Wednesday). Authors will stand by their posters between 12:30 and 14:30 to answer questions and provide further information on their study results on their presentation day. Late breaker posters are also displayed for the duration of the conference in the Poster Exhibition area. | |

**Track A > Basic Science**

| TUPEA049-P050 | Viral origins and evolution |
| TUPEA049 Phylogenetic estimation of the temporal spread of hepatitis C genotype 1a in North America |
| TUPEA050 Origin and evolutionary history of HIV-2 in Cuba |
| L.Y. Machado, O. Martinez, H.M. Diaz, M. Blanco, E. Noa, D. Romay, M. Dubed |
| Cuba |

| TUPEA051-A062 Viral diversity, phylogenetics, phyloodynamics |
| TUPEA051 Molecular epidemiology of clinical HIV-1 pol sequences isolated between January 2009 and July 2013 in Cuba |
| Cuba |
| TUPEA052 The Local Dissemination Impact of the HIV-1 env LDI tripeptide a4ß7 binding motif |
| Brazil |
| TUPEA053 Evolution of the HIV-1 envelope gene during suppressive cART |
| J. Bader, M. Däumer, A. Thielen, J. Böni, M. Gorgievski-Hrisofo, T. Klimkait, The Swiss HIV Cohort Study |
| Switzerland |
| TUPEA054 Multiplexed highly-accurate next-generation sequencing of mixtures of full-length HIV genome variants |
| D. Dilibria, J. Ting-Chien, D. Monaco, M. Brown, Z. Ende, M. Deymier, L. Yue, E. Paxinos, S. Allen, A. Tirado-Ramos, E. Hunter |
| United States |
| TUPEA055 HIV-1 circular recombinant CRF02-AG: rapid spread in Russia and neighboring countries |
| Russian Federation |
| TUPEA056 A new framework for reconstructing epidemic dynamics from virus sequences: model validation and application to the HIV CRF07-BC epidemic in China |
| A. Poon |
| Canada |

**TUPEA057** Prevalence, evolutionary dynamics and transmission pattern of HCV, HIV-1 and HPGV among injecting drug users

K.T. Ng, Y. Takebe, Y.M. Lee, A. Wahab, W.Z. Chow, H.A. Abed Al-Darraji, L.Y. Ong, A. Kamarulzaman, K.K. Tee

**TUPEA058** Identification and genetic characterisation of a novel HIV-1 circulating recombinant lineage (CRF74_01B) among people who inject drugs in Malaysia


**TUPEA059** Kive: a framework for version control of bioinformatic pipelines and data, and its application to HIV resistance genotyping

R. Liang, E. Martin, R. McCloskey, D. Kirkby, J. Nakagawa, T. Nguyen, P.R. Harrigan, A. Poon

**TUPEA060** Newly diagnosed HIV-1 infections in Spain frequently group in clusters of subtype B and non-subtype B genetic forms


Spain

**TUPEA061** Prevalence of defective HIV-1 genome in HIV-infected patients on long-term cART and correlation with characteristics of patients

C. Psomas, B. Montès, S. Eymard-Duvernay, V. Le Moing, E. Delaporte, J. Reynes, A. Makinson

France

**TUPEA062** Full-length ultra-deep sequencing of HIV-1 transmission partners reveals the impact of intra-host evolution on immune control


United Kingdom

**TUPEA063** Viral fitness

**TUPEA064** Drug susceptibility and viral fitness of integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations in combination

K. Andreatto, M. Miller, K. White

United States

**TUPEA065** SIV CTL escape mutations resulting in loss of viral fitness can be maintained after transmission into MHC-I-mismatched hosts


Japan

**PEA066-A068** Antiretroviral resistance mechanisms

www.ias2015.org 1 / 17
Transmission dynamics of local networks of transmitted resistance to NNRTIs suggest an increasing incidence over time in Greece: the added value of molecular epidemiology to public health
Greece

HIV resistance pathways support the use of lamivudine (3TC) and dolutegravir (DTG) in combination
T. Mespléde, D. Singhroy, B. Spira, M. Wainberg
Canada

Evolution of HIV-1 integrase following selection of R263K with further dolutegravir treatment: a case report from the P1093 study
C. Vavro, P. Palumbo, A. Wizina, C. Alvero, B. Graham, T. Fenton, R. Hazra, E. Townley, A. Buchanan, J. Horton, R. Viani, P1093 Study Group
United States

Host genetics of HIV susceptibility and disease progression

Degradation of HIV-1 Nef by ubiquitin (Ub) specific protease 15 (USP15)
I.-W. Park, D. Pyeon
United States

Independent association of host immunogenetic factors with vertical HIV transmission
J. Mania-Pramanik, S. Ahir-Bist, V. Chavan, S. Kerkar, P. Samant-Mavani, R. Nanavati, P. Mehta
India

Expression analysis of a4 integrin and related genetic polymorphisms in HIV acquisition and disease progression of infected individuals
Brazil

Human leukocyte antigen (HLA) typing and novel allele description by next generation sequencing in HIV-1-infected individuals from Southern Brazil
I. Prellwitz, B. Alves, E. Sprinz, H. N. Seuanez, M. Soares, E. Soares
Brazil

Absence of an association between mannose binding lectin deficiency and HIV-1 disease progression in an adult population in Zimbabwe
South Africa

Global mapping of HIV-1 and host-cell molecular interactions
Canada

Preclinical drug development

TLR7 agonist GS-9620 is a potent inhibitor of acute HIV-1 infection in human PBMCs
United States

A novel acylguanidine-based inhibitor of HIV-1 egress
Canada

Novel CD4-mimetic small molecules show enhancement of the neutralization activity of anti-cryptic V3 neutralizing antibody, KD-247
S. Harada, Y. Irahara, H. Tamamura, T. Matano, S. Matsushita, K. Yoshimura
Japan

BMS-955176: characterization of a 2nd-generation HIV-1 maturation inhibitor
United States

Small molecule activator of protein phosphatase 1 (SNAP1) activates latent HIV-1 virus
United States

Discovery and anti-HIV-1 activity of a new class of diheteroarylamide-type anti-HIV-1 agents acting on HIV-1 alternative splicing
P. Cheung, D. Horant, L. Bandy, S. Karagiousov, P. R. Harrigan, B. Chabot, D. Grierson
Canada

Discovery of novel HIV-1 inhibitors from natural products
Canada

Development of efficient parallel synthesis strategies for the generation of compound libraries of anti-HIV agents that alter HIV alternative splicing
Canada

Preclinical microbicide development

Antiviral activity of 5-Hydroxytyrosol, a compound libraries of anti-HIV agents synthesis strategies for the generation of natural products
Canada

Protection from HIV-1 infection by S-layer mediated display of anti-HIV proteins that alter HIV alternative splicing
Canada
Risk of virologic rebound in HIV-infected patients on HAART with very low-level viremia
Hong Kong, SAR of China

Minimal HIV-1 Gag epitope presentation in a T cell line during reactivation
X.T. Kuang, G. Anmole, P. Mvimani, M.A. Brockman
Canada

Vorinostat, panobinostat and romidepsin nonselectively activate transcription from quiescent HIV-1 proviruses in HIV-infected individuals on long-term suppressive antiretroviral therapy
K. Barton, T.A. Rasmussen, M. Tolstrup, W. Shao, B. Hiener, R. Olesen, A. Winkelmann, A. Solomon, L. Østergaard, S.R. Lewin, O.S. Søgaard, S. Palmer
Australia

Combinatorial CRISPR/Cas9 approaches targeting different steps in the HIV life cycle efficiently limits viral reactivation and halts viral replication
M. Nilhus, D. de Jong, F. Wolters, E. Wiertz, R.J. Lebbink
Netherlands

Universal Tre-recombinase (uTre) specifically targets the majority of primary HIV-1 isolates
Germany

Polyvalent immune responses correlate with lower number of HIV-infected CD4 T cells in chronically infected subjects treated with autologous RNA pulsed DC therapy
I. Tcherepanova, J. Krisko, I. Harris, A. Gamble, W. Lewis, M. DeBenedette, C. Nicolette
United States

Latency reversal Agent (LRA) romidepsin reactivates latent virus in two rhesus macaque (RM) models of controlled SIV infection in the absence of antiretroviral therapy (ART)
B. Policicchio, E. Brocca-Cofano, C. Xu, D. Ma, T. He, H. Li, G. Haret-Richter, T. Dunsmore, G. Shaw, R. Ribeiro, I. Pandrea, C. Apetrei
United States

Robust HIV-specific T cells in post-treatment controllers from the VISCONTI cohort
A. Samri, V. Avettand-Fenoël, L. Hocqueloux, C. Bacchus-Souflan, A. Cheret, E. Emarre, B. Descours, A. Saez-Cirion, C. Rouzioux, B. Audran, VISCONTI Study Group
France

Net inhibition for enhanced NK cell killing of cells expressing reactivated HIV-1
E. Scully, A. Lockhart, W. Garcia Beltran, A. Bodair, M.-C. Rouyze, S. Benichou, D. Kurtzkes, M. Alfeld
United States

Emergence of infectious treatment-resistant HIV after provirus-directed endonuclease therapy
H.S. De Silva Feeligwe, M. Aubert, D. Stone, K.R. Jerome
United States

Selection and evaluation of specific single chain antibodies against gp41 of HIV
F. Nejatollahi, H. Joulaei, R. Robati
Iran, Islamic Republic of

Antibody-dependent cellular cytotoxicity against cells latently infected with HIV
W.S. Lee, M. Lichtfuss, M.S. Parsons, S. Kent
Australia

Potent and broad neutralizing activity of small antibody fragments targeting CD4i (CD4-induced) epitope
K. Tanaka, T. Kuwata, Y. Maruta, K. Ramirez, M. Alam, Y. Egami, Y. Kawanami, S. Matsushita
Japan

A novel TLR-9 agonist (MGN1703) activates NK-cells and enhances NK-cell mediated viral killing of HIV-1 infected CD4+ T cells ex vivo
Denmark

HIV testing (including new algorithms, rapid/point of care testing and strategies)
R. Serrano, M. Philyaw, D. Lodin
United States

High acceptability of rapid HIV test in Argentina: experience during a seroprevalence study in vulnerable groups
Argentina

Novel diagnostic peptide epitope biomarkers for detection and identification of recent and longstanding HIV infection using the Europium Nanoparticle Immuno Assay (ENIA)
United States

Performance of the determine HIV 1/2 Ag/Ab combo rapid test for detecting acute HIV infection: a systematic review and Bayesian meta-analysis
R. Serrano
United States

What individual and contextual factors are associated with rapid HIV test utilization in the U.S.?
M. Smallwood, R. Vijn, B. Nauche, B. Lebouché, L. Joseph, N. Pant Pai
Canada

Roll-out of a national early infant diagnosis program in Papua New Guinea, 2008-2013
I. Silas, P. Desai, E. Lavu, M. Kiromat
Papua New Guinea

Performance of the Trinity Biotech Uni-Gold HIV 1/2 rapid test as a first-line screening assay for gay and bisexual men compared with 4th generation immunoassays
Australia
Tuesday 21 July | Poster Exhibition

**TUPEB222**  Evaluation of SD bioline HIV Ag/Ab assay for detection acute HIV infection (AHI)
A. Drake, D. Matembo, J. Kinuthia, S. McClelland, J. Klaushner, G. John-Stewart
Kenya

**PB223**  CD4 measurement (including point of care diagnostics)
**TUPEB223**  A meta-analysis of the performance of the PimaTM CD4 for point of care testing
L. Scott, J. Campbell, L. Kestens, L. Vojnov, T. Peter, W. Stevens
South Africa

**TUPEB224-B226**  Viral load measurement (including point of care diagnostics)
**TUPEB224**  Assessment of new technology for the scale up of HIV viral load monitoring in South Africa
South Africa

**TUPEB225**  Alere TM q HIV-1/2 POC assay on plasma rather than whole blood, yields adequate viral load results
L. Hans, N. Ndongwane, A. Mayne, L. Gonzales, S. Carmona
South Africa

**TUPEB226**  Accuracy of HIV viral load testing with dried plasma spot (DPS) samples for identifying virological failures: primary data from 11 field studies
L. Vojnov, C. Zeh, M. Prescott, C. Boeke, T. Peter, C. Yang, DPS for VL Diagnostics
Tanzania, United Republic of Tanzania

**TUPEB227-B234**  Drug resistance testing
**TUPEB227**  Alarming levels of drug resistance in HIV-1-infected patients failing treatment in Cuba
Cuba

**TUPEB228**  Prevalence of primary HIV drug resistance by short transcribe transcriptase genotypic resistance assay in Thailand
S. Kiertiburanukul, S. Pinsai, W. Chantratita, E. Pakomsim, M. Leechawengwong, N. Siriyakorn, S. Sungkanuparph
Thailand

**TUPEB229**  Establishment of an Illumina MiSeq-based HIV drug resistance testing platform
H. Ji, T. Taylor, E. Enns, M.-K. Gauthier, R. Capina, B. Liang, G. Van Domselaar, P. Sandstrom, J. Brooks
Canada

**TUPEB230**  Validating the World Health Organization HIV drug resistance early warning indicators
L. Lourenco, H. Ma, R. Harrigan, P. Sereda, J. Montaner, V. Lima
Canada

**TUPEB231**  High prevalence of NNRTI HIV drug resistance in children under 18 months of age recently diagnosed with HIV: results from a national survey in South Africa
S. Carmona, K. Steegeen, G. Hunt, L. Morris, I. Sanne, W. Stevens, G. Sherman
South Africa

**TUPEB232**  Moderate levels of pre-treatment HIV-1 antiretroviral drug resistance observed in a national survey in South Africa
K. Steegeen, S. Carmona, M. Bronze, M.A. Papathanasopoulos, G. Van Zyl, D. Goedhals, W. Macleod, I. Sanne, W.S. Stevens
South Africa

**TUPEB233**  Prevalence of HIV-1 cross-resistance against dolutegravir and elvitegravir in raltegravir-experienced patients in Germany over the past five years
F. Wiesmann, T. Goodarzi, P. Braun, H. Knechten
Germany

**TUPEB234**  High frequency of genotypic resistance in HIV-1-infected patients on highly active antiretroviral therapy with persistent low viremia
D. Pellegrino, J. Souza Cavalcanti, J.L. Ferreira, L.F. Brígido Macedo
Brazil

**TUPEB235-B237**  Diagnostics of co-infections (including syphilis, TB, Cryptococcus, hepatitis B, C and other)
**TUPEB235**  Global performance of GeneXpert (Xpert MTB/RIF, Cepheid) using standardized verification and external quality assessment material
L. Scott, V. Magida, A. David, V. Deyde, A. Adelekan, C. Gilpin, R. Coombs, W. Stevens, Xpert MTB/RIF EQA consortium
South Africa

**TUPEB236**  Routine eye screening by an ophthalmologist is clinically useful for HIV-1-infected patients with CD4 count less than 200 /μL
T. Nishijima, S. Yashiro, K. Teruya, Y. Kikuchi, N. Kaitai, H. Gatanaga, S. Oka
Japan

**TUPEB237**  Association between transient elastography (TE) scores and AST to platelet ratio index (APRI) among HIV/HCV co-infected patients
M. Harris, M. Hull, A. Moghadam, G. Larsen, W. Zhang, B. Canase, T. Kozi, B. Vip, R. Hogg, J. Montaner
Canada

**TUPEB238-B255**  Hepatitis C
**TUPEB238**  Decreasing prevalence of HCV-HIV co-infection (2004-2013) in Madrid, Spain
Spain

**TUPEB239**  No difference in safety profiles comparing 12- and 24-week HCV treatment durations in HCV genotype 1 and HIV-1 co-infected patients: results from TURQUOISE-I
United States

**TUPEB240**  Low incidence of reinfection with hepatitis C virus after successful treatment in Montreal
Canada

**TUPEB241**  Fibrosis regression is possible after a successful treatment of hepatitis C even with cirrhosis
B. Trottier, E. Huchet, M. Poliquin, M.-M. Bellon, S. Vézina, C. Galanakis, D. Longpré, S. Lavoie, R. Thomas, N. Machouf
Canada
<table>
<thead>
<tr>
<th>Session Code</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>TUPEB243</td>
<td>Pro-inflammatory gene expression remains altered after successful HCV treatment</td>
<td>P. W aldron, M. Holodniy</td>
<td>United States</td>
</tr>
<tr>
<td>TUPEB244</td>
<td>Genetic variation in IL-6 and HLA-DQB1 genes are associated with spontaneous clearance of hepatitis C virus infection</td>
<td>P. Waldron, I. Belltskaya-Levy, A. Chary, L.C. Lazzeroni, A. Monto, J. Ryan, M. Holodniy</td>
<td>United States</td>
</tr>
<tr>
<td>TUPEB245</td>
<td>Favourable IFNL3 genotypes and liver fibrosis in hepatitis C (HCV) co-infected individuals from the Canadian Cohort</td>
<td>N. Moquette, R. Platt, M. Hull, C. Cooper, S. Walmesley, J. Gill, M. Klein, Canadian Cohort</td>
<td>Canada</td>
</tr>
<tr>
<td>TUPEB246</td>
<td>The risk of cardiovascular disease and death over 10 years in HIV/HCV co-infected patients with and without steatosis</td>
<td>C. Down, N. Mehta, K. Marks</td>
<td>United States</td>
</tr>
<tr>
<td>TUPEB248</td>
<td>National trend and characteristics of acute hepatitis C among HIV-infected individuals: a matched case-control study</td>
<td>? Taiwan, June 2001 - December 2014</td>
<td>Taiwan, China</td>
</tr>
<tr>
<td>TUPEB249</td>
<td>High efficacy and low relapse rates observed with 8 or 12 weeks of LDV/SOF STR in GT1 HCV infected treatment-naive, non-cirrhotic patients with pretreatment HCV RNA &lt; 6 million IU/mL</td>
<td>D.L. Wyles, P.Y. Kwo, S. Zeuzem, G. Foster, P.E. Sax, T. McLean, S. Seyediakazemi, C. Avila, B. Kreter, P.S. Pang, K. Kowdle</td>
<td>United States</td>
</tr>
<tr>
<td>TUPEB250</td>
<td>The impact of serosorting on hepatitis C and HIV co-infection amongst men who have sex with men: a modelling analysis</td>
<td>L. MacGregor, N. Martin, A. Ganesh, F. Hickson, P. Weatherburn, P. Vickers</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>TUPEB251</td>
<td>Pending availability and affordability of new HCV regimens in resource-limited settings, should HIV-HCV co-infected patients start receive peg-interferon and ribavirin which just started to be affordable?</td>
<td>G. Jourdain, J. Figon, K. Thetket, P. Leenasrinakul, V. Klinbuayaem, S. Khususwan, C. Bowonwatanawong, S. Chalermpanmetatagul, T.R. Cressev, L. Decker, N. Durier, N. Salvadori, N. Ngo-Giang-Huong, PHPT HIV-HCV Treatment Group</td>
<td>Thailand</td>
</tr>
<tr>
<td>TUPEB253</td>
<td>PegIFN-a 2a dose-dependent reduction in HIV-DNA levels during the first 4 weeks of treatment in HIV-1/HCV co-infected patients</td>
<td>O.-J. BenMarzouk-Hidalgo, A. Torres-Cornejo, A. Gutierrez-Valencia, R.M. Ruiz-Valderas, P. Viciana, L.F. López-Cortés</td>
<td>Spain</td>
</tr>
<tr>
<td>TUPEB254</td>
<td>Global systematic review and meta-analysis of the seroprevalence of HBV and HCV infection in HIV-infected persons</td>
<td>P. Easterbrook, L. Platt, E. Gower, H. Razavi, K. Sabin, P. Vickerman</td>
<td>WHO</td>
</tr>
<tr>
<td>PEB256-B260</td>
<td>Other adverse reactions and complications of ART</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TUPEB256</td>
<td>Adverse drug reactions associated with integrase strand transfer inhibitors (INSTI) in clinical practice: post-marketing experience with raltegravir, elvitegravir-cobicistat and dolutegravir</td>
<td>K.J. Lepik, A. Nohpali, B. Yip, K.J. Toy, L. Akagi, J.S.G. Montaner, S. Guillemi, R. Hogg, R. Barrios</td>
<td>Canada</td>
</tr>
<tr>
<td>TUPEB257</td>
<td>Physiological concentrations of combination antiretroviral therapy drugs that affect mitochondrial DNA (mtDNA) quantity and quality in cell culture models</td>
<td>S. Saberi, F. Valentino, A. Ziada, A. Hsieh, I. Gadawski, H.C. Côté, the CIHR Team in Cellular Aging and HIV Comorbidities in Women and Children (CARMa)</td>
<td>Canada</td>
</tr>
<tr>
<td>TUPEB259</td>
<td>Serious non-AIDS events and biomarker changes in HIV-1-infected individuals</td>
<td>M. Sunil, N. Utabay, R. Arduino, M. Martinez, X. Yu, A. Somasundaram, M. Nigalaye, T. Bell</td>
<td>United States</td>
</tr>
<tr>
<td>TUPEB260</td>
<td>Heterogeneity of preferences for antiretroviral drug regimens from the perspective of people living with HIV</td>
<td>A. Bayoumi, S. Miles, T. Lin, D. Regier, T. Antoniou, L. Park-Wyllie, C. Strike, J. Hoch, J. Raboud</td>
<td>Canada</td>
</tr>
<tr>
<td>PEB261</td>
<td>Clinical trials: phase III</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PEB261</td>
<td>Safety and efficacy of DTG by age, race and gender: subgroup analysis of 96-week results from treatment-naive patients in phase III trials [SPRING-2 (ING113086), SINGLE (ING114467) and FLAMINGO (ING114915)]</td>
<td>J. Koteff, R. Cuffe, C. Ganier, A. Zolopa, A. Murungi, B. Wynne, M. Aboud</td>
<td>United States</td>
</tr>
</tbody>
</table>

www.ias2015.org
**Tuesday 21 July**

**PEB262-263** Timing of therapy initiation

**TUPEB262**
- Short course versus deferred therapy for the treatment of HIV primary infection: a meta-analysis
  - J. Amio, PHIT, M Study Group
  - Australia

**TUPEB263**
- CD4 reconstitution is related to CD4 at effective antiretroviral treatment initiation & B262; K. Calkins, J. Eron, A. Abraham, K. Buchacz, M. Horberg, J. Tate, S. Napravnik, R. Moore, R. Bosch, B. Lau
  - United States

**PEB264-265** First-line therapy

**TUPEB264**
- Comparison of the effectiveness, tolerability and efficiency (cost-effectiveness) of an antiretroviral regimen administered as a single tablet regimen (STR) vs. multiple tablet regimens (MTR) in antiretroviral naïve HIV patients
  - Spain

**TUPEB265**
- Treatment outcomes among older HIV-infected adults in Jos, Nigeria
  - Nigeria

**TUPEB266**
- ANRS 12168 - DynaM-O: a 48 weeks-prospective study to compare the immuno-virological and clinical responses to HAART between HIV-1 group O and group M-infected patients
  - C. Rouanfack, M. Vray, A. Kfutwah, A. Aghokeng, A. Vesterdahl, J. Zack
  - Cameroon

**TUPEB267**
- "CD4 explorers" and "CD4 peak achievers" under ART in a large Italian cohort of HIV-infected subjects
  - Italy

**PEB268** Second-line therapy

**TUPEB268**
- HIV-1+ patients submitted to second line therapy display a comparable immunological biosignature to HIV+ uninfected patients while first line therapy partially recovers immune response to a non-infected status
  - Brazil

**TUPEB269** Therapy in highly treatment-experienced persons

**TUPEB269**
- Regimen switching and virological response in treatment experienced HIV+ patients receiving an integrase inhibitor based regimen: an Australian cohort study
  - N. De La Matx, D. Cooper, D. Russell, D. Smith, I. Woolley, M. O-Sullivan, S. Wright, M. Law
  - Australia

**PEB270** Simplification (with one- or two-agent regimens) and switch studies

**TUPEB270**
- Switch from PI/rtv +2 nucleos(t)ides to RPV+DRV/rtv maintains HIV suppression and is well tolerated
  - F. Maggiolo, D. Valent, A. Callegaro, E. Di Filippo, G. Gregis, M. Rizzi
  - Italy

**PEB271-B275** Pharmacokinetics / pharmacodynamics / role of therapeutic drug monitoring

**TUPEB271**
- Renal safety of tenofovir and amphotericin co-administration in treatment of cryptococcal meningitis
  - Uganda

**TUPEB272**
- The pharmacokinetic profiles of dolutegravir in Japanese HIV-1-infected patients
  - M. Takahashi, M. Mizutani, M. Kato, H. Togami, S. Matsumoto, Y. Yokomaku
  - Japan

**TUPEB273**
- Composite CYP2B6/CYP2B6 genotype and risk for suicidality among HIV-infected individuals randomly assigned to initiate efavirenz-containing regimens in AIDS Clinical Trials Group studies
  - United States

**TUPEB274**
- Frequency of tablet remnants of nevirapine extended-release in stools and its impact on virological outcome in HIV-infected Taiwanese: a prospective cohort study
  - Taiwan, China

**TUPEB275**
- Bioequivalence of two dosage strength fixed-dose combination formulations of F/TAF
  - J. Zack, S. West, M. Rhee, R. Yu, A. Vu, B. Kearney
  - United States

**PEB276-279** Drug interactions

**TUPEB276**
- Rifabutin for treating tuberculosis in HIV-infected adult patients receiving boosted protease inhibitor containing ART regimen: experiences of neutropenia from an urban clinic
  - T. Mudzviti, T. Shamu, C. Chimbetete, C.C. Maponga, G.D. Morse
  - Zimbabwe

**TUPEB277**
- HIV-1 attachment inhibitor prodrug BMS-663068: interactions with rifabutin, with or without ritonavir, in healthy subjects
  - United States

**TUPEB278**
- Drug interactions between psychiatric drugs and antiretroviral therapy, adherence and clinical outcomes
  - H. Knobel, E. Molas, A. Retamero, D. Echeverria, A. Guelar, M. Florit, S. Luque
  - Spain

**TUPEB279**
- Pharmacokinetics and drug interaction potential of multiple-dose tenofovir alafenamide and rilpivirine
  - R. Begley, F. Cheng, E. Lawson, H. Graham, H. Cao, A. Vesterdahl, J. Zack
  - United States
Tuesday 21 July | Poster Exhibition

**PEB280-B289 Antiretroviral drug resistance**

**TUPEB280**
High rate of transmitted drug resistance in treatment-naïve HIV-infected VCT clients in southern Taiwan, 2007-2014

Taiwan, China

**TUPEB281**
Ten year prevalence of HIV-1 drug resistance mutations in New South Wales, Australia

A. Pinto, A. Carrera, H. Salem, K. Thapa, A. Shaik, P. Cunningham, R. Gorsia, D. Dwyer, D. Cooper, A. Kelleher
Australia

**TUPEB282**
Accuracy of WHO guidelines on management of adult patients on ART with unsuppressed viral load: a prospective multicenter study in rural Lesotho

Switzerland

**TUPEB283**
Projecting the epidemiological effect, cost-effectiveness and transmission of HIV drug resistance in Vietnam associated with viral load monitoring strategies

Australia

**TUPEB284**
HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: analysis of emergent viral drug resistance through 48 weeks of follow-up

M. Latallade, N. Zhou, S.R. Toshi, S. Lee, D.A. Stock, G.J. Hanna, M. Krystal, for the AI438011 Study Team
United States

**TUPEB285**
Analysis of HIV drug resistance in adults receiving early antiretroviral treatment for HIV prevention: results from the HPTN 052 trial

United States

**TUPEB286**
Viral blips were infrequent and similar in treatment-naïve adults treated with rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study

D. Porter, R. Kulkarni, W. Garner, M. Miller, K. White
United States

**TUPEB287**
Virological response and HIV drug resistance patterns in individuals on first line therapy for at least 4 years without routine viral load measurements: implications for second line regimens

Uganda

**TUPEB288**
HIV-1 antiretroviral resistance patterns in patients failing NNRTI-based 1st-line treatment: results from a national survey in South Africa

K. Steegen, M. Bronze, M.A. Papathanasopoulos, G. Van Zyl, D. Goedhals, W. Macleod, I. Sanne, W.S. Stevens, S. Carmona
South Africa

**TUPEB289**
Prevalence of protease inhibitor and triple-class resistance in patients failing 2nd-line ART: results from a national survey in South Africa

K. Steegen, M. Bronze, M.A. Papathanasopoulos, G. Van Zyl, D. Goedhals, W. Macleod, I. Sanne, W.S. Stevens, S. Carmona
South Africa

**PEB290-B293 Adherence**

**TUPEB290**
Influence of the adherence to antiretroviral therapy in the effectiveness of the boosted protease inhibitor dual or monotherapy

H. Knobel, A. Retamero, A. Guelar, M. Florit, E. Molas, M. Montero, D. Echeverría, O. Ferrandez, S. Luque
Spain

**TUPEB291**
Persistent effect of early (M4) adherence to antiretroviral treatment on long-term virological response in HIV-infected patients: results from the 11-year follow-up of the ANRS CO8 APROCO-COPILOTE cohort

C. Protopopescu, M.P. Carrieri, F. Raffi, L. Hardel, A. Sobel, C. Perronne, C. Jadand, J. Pierret, B. Spire, C. Leport, the ANRS CO8 APROCO-COPILOTE Study Group
France

**TUPEB292**
HIV patient preferences for simplified treatment regimens and impact on self-rated treatment adherence

M. Orme, A. Miners, C. Sabin, F. Rogatto, G. Reilly, R. Perard
United Kingdom

**TUPEB293**
Physical and sexual violence independently correlated with reduced adherence to ART among women sex workers living with HIV in Vancouver, Canada

Canada

**PEB294-B295 Complementary and traditional medicines**

**TUPEB294**
Thalidomide lead to an increase in T cell activation and inflammation on antiretroviral naive HIV-infected individuals

United States

**PEB295**
Effects of short-term probiotic ingestion in children with HIV-1 infection

Japan

**PEB296-B298 Curative interventions (including those aimed at reservoir depletion)**

www.ias2015.org 7 / 17
Tuesday 21 July | Poster Exhibition

**TUPEB296**
Reduction in total HIV-1 proviral DNA following re-boost immunizations using the peptide-based therapeutic vaccine candidate, Vacc-4x, during ART
Norway

**TUPEB297**
A feasibility study of weight-based pegylated IFN-a2b immunotherapy to target persistent HIV-1 on ART
United States

**TUPEB298**
Optimized antiretroviral therapy during allogeneic hematopoietic stem cell transplantation in HIV-infected individuals
United States

**PEB299**
Clinical approaches to drug and alcohol dependence treatment: harm reduction

**TUPEB299**
Impact of opioid substitution therapy on antiretroviral therapy: a systematic review and meta-analysis
A. Low, G. Mburu, C. Davies, C. French, M. May, S. Mclean, T. Rhodes, L. Platt, A. Guise, P. Vickerman
United Kingdom

**PEB300-B302**
Diagnosis of HIV disease in children and adolescents (including early infant diagnosis)

**TUPEB300**
Adolescent representation among clients accessing HIV testing at a large tertiary facility in north-central Nigeria
A. Ibrahim, S. Ereka, C. Onuchikwu, M. Essen, V. Tepper, M. Charurat, H. Swomen, W. Blattner, N.A. Sam-Agudu
Nigeria

**TUPEB301**
Loss to follow-up along the early infant diagnosis care continuum in Kenya
United States

**TUPEB302**
Low birth HIV infection rate in infants from high-risk-for-transmission pregnancies in South Africa
South Africa

**PEB303-B307**
ARV management strategies: children and adolescents cohort studies

**TUPEB303**
High sensitivity CRP (hsCRP) levels in long-term survivors of perinatal HIV infection
K. Kancheria, S. Kalyanam, N. Desai
United States

**TUPEB304**
Durability of first-line antiretroviral therapy (ART) in children in the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC)
R.L. Goodall, I.J. Collins, T. Childs, C. Foster, L. Ene, C. Smit, C. Kahler, A. Judd, D. Gibb, European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) in EuroCoord
United Kingdom

**TUPEB305**
Adolescents are at higher risk of attrition from HIV care: results from a cohort study in Ethiopia
Ethiopia

**TUPEB306**
12-month response to early LPV-based antiretroviral therapy in West-African children treated before the age of 2 years, the MONOD ANRS 12206 cohort
France

**TUPEB307**
Determinants of durability of first-line ART regimen and time from first-line failure to second-line ART initiation. The IeDEA paediatric West African Database (pWADA)
France

**PEB308**
Clinical issues in men who have sex with men

**TUPEB308**
Hospitalisation and predictors of morbidity in community-based cohorts of HIV- positive and -negative gay and bisexual men
Australia

**PEB309-B312**
Clinical issues in people who use drugs

**TUPEB309**
Factors associated with ART adherence and plasma HIV-1 RNA suppression among crack cocaine users in Vancouver, Canada
K. Hayashi, E. Wood, P. Nguyen, S. Guillemi, R. Hogg, J. Montaner, T. Kerr, M.-J. Milloy
Canada

**TUPEB310**
Advanced liver fibrosis and mortality of HIV/HCV co-infected patients with alcohol use disorders
P. Zuluaga, D. Fuster, F. Bolañ, A. Sanvisens, I. Rivas, M. Torres, J. Tor, R. Muñoz
Spain

**TUPEB311**
Discharge against medical advice from the HIV ward at St. Paul’s Hospital, Vancouver, British Columbia, Canada from 2005-2014
Canada

**TUPEB312**
Prescription opioid injection is strongly linked with illicit drug-related vulnerability and plasma HIV-1 RNA viral load detectability among HIV-positive illicit drug users in a Canadian setting
S. Lake, T. Kerr, R. Hogg, S. Guillemi, H. Dong, J. Montaner, E. Wood, M.-J. Milloy
Canada

**PEC499-C501**
PEP

**TUPEC499**
Delayed HIV seroconversions in patients receiving post-exposure prophylaxis (PEP)
Spain
Tuesday 21 July | Poster Exhibition

**TUPEC500** Post-exposure prophylaxis outcomes for survivors of sexual assault in resource poor settings: evidence from rural South Africa
C.R. Carty, E. Toska, T. Mukaro, F. Nicholson
South Africa

**TUPEC501** Awareness of post-exposure prophylaxis (PEP) among a cohort of gay, bisexual and other men who have sex with men (MSM) in Vancouver, Canada
A. Rich, M. Hull, N.J. Lachowsky, Z. Cui, P. Sereda, L. Charest, S. Lavoie, E. Hutchet, D.A. Murphy, B. Trottier, N. Machouf
Canada

**TUPEC502** Willingness to receive PrEP among HIV-uninfected Chinese MSM who are users of a popular geosocial networking application
H.T.H. Wong, S.S. Lee, D.P.C. Chan
Hong Kong, SAR of China

**TUPEC503** PrEP in real-life settings: good adherence and no increase in high-risk behavior
R. Thomas, C. Galanakis, D. Longpré, J.-P. Kerbs, L. Charest, S. Lavoie, E. Huchet, D.A. Murphy, B. Trottier, N. Machouf
Canada

**TUPEC504** Concerns and benefits of PrEP: lessons from the national PrEP demonstration project formative study in Nigeria
Y. Nancin Dadem, J. Idoko, M. Folayan, O. Grace Kolawole, J. Aneinih, E. Alhassan
Nigeria

**TUPEC505** HIV pre-exposure prophylaxis (PrEP) product preference among women in the VOICE-D (MTN-003D) study
E. Luecke, H. Cheng, K. Woebter, T. Nakyanzi, O. Muniaiwa, A. van der Straten
United States

**TUPEC506** Patient-provider communication about sexual behaviors and pre-exposure prophylaxis: results from a national online survey of men who have sex with men in the United States
United States

**TUPEC507** Absence of sexual behavioral disinhibition in a PrEP adherence trial: considerations for medical providers who prescribe PrEP for men who have sex with men (MSM)
S. Elsesser, K. Biello, S. Taylor, J. Tomassili, S. Safren, K. Mayer
United States

**TUPEC508** Significant increases in HIV pre-exposure prophylaxis (PrEP) uptake in Boston, a Boston Community Health Center in 2014: who are the recent users?
K. Mayer, D. Krakower, K. Levine, C. Grasso, M. Gelman
United States

**TUPEC509** Pre-exposure prophylaxis (PrEP) knowledge and use in a population-based sample of younger Black men who have sex with men (YBMSM) in Chicago
A. Khanna, S. Michaels, B. Skaathun, E. Morgan, L.E. Young, P. Schumm, J.A. Schneider, UConnect Study Group
United States

**TUPEC510** PrEP in the real world: implementation of PrEP in a medium-sized city community health clinic
United States

**TUPEC511** Fertility intentions, pregnancy and PrEP use in African HIV serodiscordant couples
United States

**TUPEC512** Differences in HIV pre-exposure prophylaxis use and intention to use between stimulant and alcohol-using men who have sex with men in Boston, United States
C. Oldenburg, J. Mitty, K. Biello, E. Closson, K. Mayer, M. Mimiaga
United States

**TUPEC513** Text messaging responses correlate with tenofovir-diphosphate dried blood spot concentrations among men who have sex with men on pre-exposure prophylaxis
J. Blumenthal, D. Moore, S. Jain, K. Corado, M. Dube, J. Young, S. Sun, P. Anderson, S. Morris, R. Haubrich, California Collaborative Treatment Group
United States

**TUPEC514** PrEP utilization estimates in Australia
I. Zablotska, G. Prestage, A.E. Grulich
Australia

**TUPEC515** HPTN 067 ADAPT: 'PrEP Ubuntu' and experiences with open-label PrEP among South African women
United States

**TUPEC516** HIV evolution in breakthrough infections in a human trial of oral PrEP with FTC/TDF
United States

**TUPEC517** HIV-negative male couples' attitudes about pre-exposure prophylaxis (PrEP), and PrEP use within the context of their relationships and sexual agreements
J. Mitchell, J.-Y. Lee, J. Bauermeister, C. Woodyatt, S. Patrick, S. Lim, P. Sullivan, R. Stephenson
United States

**TUPEC518** Risk compensation among men who have sex with men (MSM) in Southern California following the initiation of pre-exposure prophylaxis (PrEP)
J. Milam, S. Jain, D. Moore, E. Daar, M. Dube, J. Young, J. Blumenthal, S. Sun, R. Haubrich, S. Morris, CCTG 595 and 597 Study Teams
United States

**TUPEC519** Reasons for accepting or declining HIV pre-exposure prophylaxis in a diverse black US population
H. Kwakwa, R. Wahome, D. Sturgis, N. Mvula, S. Bessias
United States
Tuesday 21 July | Poster Exhibition

**PECS20** Individual and sexual network characteristics are associated with HIV serodisclosure in the global iPrEx study

United States

**PECS21** Validation of a Truvada for PrEP algorithm using an electronic medical record

United States

**PECS22** Microbicides (including vaginal and rectal microbicides)

**PECS22** Safety of cervical and vaginal biopsies in microbicide and contraceptive research

United States

**PECS23** Pharmacokinetics of tenofovir and emtricitabine delivered by vaginal tablets

United States

**PECS24** Barriers and facilitators to adherence to biomedical HIV prevention strategies

**PECS24** Factors linked to transitions in adherence to antiretroviral therapy among HIV-infected illicit drug users in a Canadian setting

B. Joseph, T. Kerr, C. Puskas, J. Montaner, E. Wood, M.-J. Milloy
Canada

**PECS25** The impact of health literacy and physician–patient dynamics on health outcomes in adult HIV patients

A. Wawryznik, A. Falcon, A. Parra, A. Rodriguez
United States

**PECS26** Approaches to improving adherence to prevention interventions

**PECS26** Prevalence and correlates of non-disclosure of maternal HIV status in Kenya

J. Kinuthia, C. McGrath, B. Odeny, B. Singa, A. Langat, A. Katana, L. Nganga, J. Pintye, G. John-Stewart
Kenya

**PECS27** African women’s perceptions of honesty and dishonesty about product use adherence in the context of HIV prevention research during the VOICE (MTN-003) trial

E. Montgomery, P. Musara, K. Woebner, J. Etima, B. Mensch, A. van der Straten
United States

**PECS28** Difficulty accessing addiction treatment predicts injection initiation among street-involved youth in a Canadian setting

K. DeBeck, T. Kerr, H. Dong, J. Montaner, E. Wood
Canada

**PECS29** Prevention for the general population

**PECS29** How do HIV-negative individuals in sub-Saharan Africa change their sexual risk behaviour upon learning their serostatus? A systematic review

S. Ramachandran, N. Condie, M. Pickles, S. Mishra
United Kingdom

**PECS30** Development and initial validation of an instrument to measure beliefs among women in Puerto Rico about biomedical interventions and the biological factors that facilitate inbound and outbound HIV transmission

K. Fitzgerald, J. Martinez Gonzalez
Puerto Rico

**PECS31** Factors associated with uptake of HIV counseling and testing in Cross River State, Nigeria

C. Oyom, M. Mbukpa, O. Idoko, G. Ekuwa, A. Oginni
Nigeria

**PECS32** Prevention for youth and adolescents

**PECS32** HIV decline associated with changes in risk behaviors among vulnerable young people in Nepal: analysis of population-based HIV prevalence surveys between 2001-2012

K. Deuba, D. Kumar Karki, A.M. Ekström, G. Tomson, G. Marrone
Sweden

**PECS33** Using peer to peer approach to promote uptake of HIV/SHR services among young people (10-24 years): experience with young key populations (YKPs) in 3 central districts of Uganda

W. Musubika, D. Bukunya, H. Ntale, P. Mpinga, R. Egadu, S. Kadokech, S. Nabadda, R. Nabossa
Uganda

**PECS34** Street culture, survival and HIV risk among street-connected girls in a resource-limited setting

Canada

**PECS35** Understanding opportunities for HIV prevention and care for street connected children and youth in western Kenya

Canada

**PECS36** Effects of the PREPARE multi-component, school-based HIV prevention programme on adolescent sexual risk behavior and access to condoms, contraception and HIV testing: cluster randomized controlled trial (RCT)

South Africa

**PECS37** Correlates of intimate partner violence perpetration among young urban Tanzanian men

M. Mulawa, H.L.M. Reyes, V. Foshee, S. Martin, L. Kajula, S. Maman
United States

**PECS38** Optimising adolescent HIV care in a large Kenyan care and treatment centre

Kenya

www.ias2015.org
Towards adolescent friendly voluntary medical male circumcision services: older adolescents report relatively less satisfaction with counseling
Tanzania, United Republic of

The impact of food insecurity on sexual HIV risk negotiation with clients among youth sex workers living with and affected by HIV
Canada

Prevention for people who use drugs, including harm reduction
PEC541-PEC549

Evidence-based recommendations for essential and novel HIV prevention and harm reduction services for people who use drugs in Canada and are at risk for HIV, HCV and other harms

Urgent need for harm-reduction interventions in Mozambique: results from the Integrated Biological and Behavioral Surveillance Survey among people who inject drugs
Mozambique

Seek, test, treat and retain (STTR) for people who inject drugs (PWID) in Kenya: findings from the third intervention period of a stepped wedge study
J. Lizcano, A. Kurth, C. Cieland, P. Cherutich
United States

More vulnerability, more risk: findings from a cross-sectional qualitative study on the multiple vulnerabilities experienced by people who inject drugs (PWID) in Bihar and Manipur, India
V. Arumugam, K. Biswas, C. Sharma, F. Joseph, S.W. Beddoe, S. Mehta, J. Robertson
India

Reach them early: identifying risk behaviours after onset of injecting to reduce sharing of injecting equipment: findings from the Hridaya drug use pattern assessment in India
India

Effective services for HIV prevention among people who inject drugs (PWIDs) in Ukraine
I. Sazonova, T. Mykhalkhuc, T. Salyuk, O. Varetska
Ukraine

Exploring HIV risks and treatment outcomes among people who use drugs enrolled in unregulated recovery house programs in British Columbia, Canada’s Lower Mainland region: a qualitative study
R. McNeU, T. Kerr, S. Anderson, L. Maher, W. Small
Canada

Controlling HIV among people who inject drugs in Eastern Europe and Central Asia: insights from modelling
P. Vickerman, L. Platt, E. Jolley, T. Rhodes, M. Kazatchkine, A. Latypov
United Kingdom

HIV risk factors associated with risky and illegal income generation among street-involved youth in a Canadian setting
T. Cheng, T. Kerr, P. Nguyen, E. Wood, K. DeBeck
Canada

Defining public disorder: conceptual implications for HIV prevention efforts
D. Werb, D. Fast
Canada

Prevention for male, female and transgender sex workers
PEC552-PEC558

Interventions for commercial sexual workers: lessons and challenges from Rakai, Uganda

Understanding high HIV risk behavior, gender identity, stigma and violence among transgender women in urban Uganda
R. King, J. Nanteza, Z. Sebyala, T. Poteat, R. Apondi, W. Hladik
United States

Transactional sex and the challenges to safer sexual behaviors: a study among male sex workers in Chennai, India
B. Thomas, K. Biello, E. Closson, P. Navakodi, A. Dhanalakshmi, S. Menon, K. Mayer, S. Safren, M. Mimiaga
United States

Prevalent syphilis predicts HIV acquisition among men who have sex with men who received money, or gifts in exchange for sex, Bangkok, Thailand

Concealment and stigma in the context of adherence to ARV therapy amongst female sex workers in Bamenda, Cameroon, a qualitative report
R.T. Nyente, F.P. Ijang, N. Atiabet, G. Njohyah, FSW-REACH OUT Study Group
Cameroon

Determinants of non-condom use among female sex workers in Iran: findings of the first national bio-behavioural study
M. Karamouzian, A. Mirzazadeh, H. Shariifi, A. Sedaghat, M. Shokoohi, A. Haghdoost
Iran, Islamic Republic of

Testing for HIV among female sex workers in Iran; findings of the first national bio-behavioural survey in 2010
H. Shariifi, A. Mirzazadeh, M. Karamouzian, M. Shokoohi, A. Sedaghat, A. Haghdoost
Iran, Islamic Republic of
Tuesday 21 July | Poster Exhibition

TUPEC559  Induced abortion among female sex workers in Iran: findings of the first national bio-behavioural study in 2010
H. Sharifi, M. Karamouzian, A. Mirzazadeh, A. Sedaghat, M. Shokoozhi, A. Haghdoot
United States

TUPEC560  Recent incarceration correlated with reduced access to HIV prevention in a longitudinal study of sex workers who inject drugs in a Canadian urban centre
M.E. Socias, K. Shannon, M. Horton, P. Nguyen, T. Lyons, R. Martin, M. Mannoe, K. Deering
Canada

PEC561-C566 Prevention for MSM
TUPEC561  The emergence of undetectable viral load as a HIV risk reduction strategy by Australian gay and bisexual men who have condomless sex with casual partners
M. Holt, T. Lea, L. Mao, I. Zablotska, G. Prestage, J. de Wit
Australia

TUPEC562  Awareness & utilization of HIV prevention innovations among men who have sex with men in Seattle
J. Hood, S. Buskin, E. Barash, D. Katz, J. Dombrowski, M. Golden
United States

TUPEC563  When and how male couples form a sexual agreement in their relationship: qualitative findings toward development of a tailored online HIV prevention 'toolkit' for at-risk HIV-negative male couples
J. Mitchell, J.-Y. Lee, J. Bauermeister, C. Woodyatt, S. Patrick, S. Lim, P. Sullivan, R. Stephenson
United States

TUPEC564  Awareness and willingness to take pre-exposure prophylaxis (PrEP) among men who have sex with men and transgender women: preliminary findings from the PrEP Brasil study
Brazil

TUPEC565  Community mobilization intervention with men who have sex with men (MSM) increases uptake of regular HIV-testing in South Africa: 12-month impact evaluation results from project Boithato
T. Lane, T. Osmand, A. Marr, S. Shade, N. Mlotshwa, A. Bilankulu, G. Gaoboepe, T. Sandfort, H. Struthers, S. Kegeles, J. McIntyre
United States

TUPEC566  An event-level analysis of substance use, relational, and psychosocial factors affecting condom use during anal intercourse among self-identified HIV-negative and unknown status gay and other MSM in Vancouver, British Columbia
Canada

PEC567-C568 Prevention for transgender persons
TUPEC567  Prevalence and correlates of injection of industrial silicone among transgender women in Argentina
M.E. Socias, T. Kerr, B.D.L. Marshall, I. Arístegui, C. Frola, P. Cahn, O. Sued
Argentina

TUPEC568  Transgenders in Ukraine: understudied and underserved
R. Kulchynska, T. Saliuk, O. Trofimenko, A. Meteliuk, M. Gates
United States

PEC569  Prevention for immigrants, mobile and displaced populations
TUPEC569  Assessment of HIV associated risk behaviour among internally displaced persons (IDPs) in Northern Nigeria
C. Ifekandu, U. Bukar, E. Jegede
Nigeria

PEC570-C573 Prevention for HIV serodiscordant couples
TUPEC570  Implementation of HIV discordant couple care and treatment program in a Kenyan referral hospital
Kenya

TUPEC571  Couples testing and immediate antiretroviral therapy among serodiscordant couples in Vietnam: implementation study in resource-limited settings affected by drug use
Vietnam

TUPEC572  Healthcare providers' understanding of HIV sero-discordance in South Africa and Uganda: implications for HIV prevention counselling
South Africa

TUPEC573  Community cultural beliefs and disclosure to primary sexual partners among women living with HIV in Brazil, Thailand and Zambia: results from HPTN063
B. Olikuku, S. Pathak, S. Li, K. Mayer, S. Safren, HIV Prevention Trials Network 063
United States

PEC574  Prevention for other vulnerable populations
TUPEC574  Perceptions of HIV burden and risk among Lake Victoria fishing communities: a qualitative study
V.C. Lee, T. Saliku, Z. Gura, E. Zielinski-Gutierrez
Kenya

PEC575  Prevention during acute and recent infection
TUPEC575  Influence of suspected source of infection on discrimination among people with acute HIV in Malawi
United States

PEC576  Prevention among HIV-infected individuals
TUPEC576  Prevention strategies during anal intercourse and prevention-related attitudes of HIV-positive gay, bisexual and other MSM in Vancouver, British Columbia
Canada

www.iassum.org  12 / 17
Tuesday 21 July | Poster Exhibition

TUPEC588 Assessing changes in HIV-related legal and policy environments in sub-Saharan Africa
L. Ferguson, S. Gruskin, I. Henry, A. Nicholson, A. Saha, T. Sellers
United States

TUPEC589 A global analysis of the role of lay providers in national HIV testing and counseling policies
D. Flynn, C. Johnson, A. Sands, V. Wong, R. Baggaley
Australia

TUPEC590 Criminalization of HIV transmission in France: knowledge of and concerns about HIV-related court-case verdicts in a representative sample of people living with HIV (ANRS VESPA2 survey)
M. Suzan-Monti, B. Demoulin, M. Celse, R. Dray-Spira, F. Lert, B. Spire, ANRS VESPA2 Study Group
France

TUPEC591 Policy and legal challenges and opportunities for HIV and drug abuse prevention among migrant tourism workers in the Dominican Republic
M. Padilla, N. Varas-Diaz, J. Colon Burgos, A. Matz-Reyes
United States

TUPEC592 Gender differences in meeting legal obligations to disclose HIV status within a cohort of HIV-positive illicit drug users in Vancouver
S. Patterson, A. Kaida, P. Nguyen, J.S. Montanier, G. Ogilvie, R.S. Hogg, M.-J. Milloy
Canada

TUPEC593 Supporting policy-level action for improved health outcomes in Zimbabwe
C. Zinyemba, A. Mahomva, E. Tumbare, A. Mushavi
Zimbabwe

PECS4-595 Community involvement in biomedical prevention

TUPEC594 Facilitating community-led action for optimal uptake of prevention of mother to child transmission of HIV (PMTCT) services in vulnerable communities: the Elizabeth Glaser Pediatric AIDS Foundation-Zimbabwe community engagement program
C. Zinyemba, E. Tumbare, E. Chinake, W. Ushamba, T. Gutaiza, A. Mahomva
Zimbabwe

TUPEC595 Engaging MSM key opinion leaders to create and sustain HIV and STIs services for a trusted community health centre
Lagos, Nigeria
Nigeria

Track D > Implementation Science

PED761-D763 Integration of prevention interventions with care/treatment

TUPE761 Effective use of task shifting in strengthening 4 symptom screening for TB disease among PLHIV in rural clinics in Northern Nigeria
Nigeria

PEC588-593 Policy-level HIV interventions including legal-policy reform

PECS81-583 Prevention in other institutional settings (including workplace / school / prison / army)

TUPEC581 HIV/AIDS in prison: a global systematic review of HIV incidence and AIDS-related mortality
K. Dolan, B. Moazen, A. Noori, S. Rahimzadeh, F. Farzadfar, F. Hariga
Australia

TUPEC582 Prevalence and correlates of occupational needle-stick injuries among active duty police officers in Tijuana, Mexico
United States

TUPEC583 Endowment training intervention: changing attitudes toward opioid substitution therapy in 30 minutes
M. Polonsky, F. Altice
United States

PECS4-587 Collectivization, mobilization, stigma reduction programmes

TUPEC584 Stigmatized health care: a challenging issue for Iranian HIV+ patients
N. Zarei, H. Joulaei, M. Amini Lari
Iran, Islamic Republic of

TUPEC585 Opinions and experiences of HIV-status disclosure to sex partners: a qualitative study with gay men in Lima, Peru
C. Sandoval, L. Najarro, K. Konda
United States

TUPEC586 Development and reliability of scales to measure stigma among men who have sex with men and female sex workers in West Africa: tools for stigma reduction programmes
A. Grosso, S. Ketende, G. Ouedraogo, S. Anato, O. Ky-Zerbo, V. Pitche, E. Papworth, S. Baral
United States

TUPEC587 Determinants of stigmatization of people living with HIV/AIDS in Burkina Faso
M. Kaboré, H. Badolo, N. Sawadogo, Y.J. Drabo, N. Méda
Burkina Faso

PEC588-593 Policy-level HIV interventions including legal-policy reform
Integrating direct provision of ART into TB services to increase ART uptake among TB-HIV co-infected clients in south west Uganda (2010-2014)
Uganda

New strategies to increase HIV case finding in hard to reach populations
Ukraine

Methods to improve provider quality, supply and tailoring of services
Are women enrolled in the PMTCT program breastfeeding their infants? Findings from a PMTCT electronic database in Zimbabwe
Zimbabwe

Quality of care and treatment for HIV-positive patients in two rural health districts in sub-Saharan Africa
S. Nahrung, M. Sarker, A. Sié, H. Masanja, H.W.F. Neuham, ARVMAC
WHO

Determinants of forecast accuracy for paediatric antiretroviral drugs in Kenya
S. Ngojo, G. Osano, E. Guantai
Kenya

HIV-infected adolescent and caregiver experiences of HIV stigma and discrimination in Kenya
L. Fischer, W. Nyandiko, M. Scanlon, M. McHenry, V. Naayu, R. Vreeman
United States

What factors are critical in improving client satisfaction with PMTCT services in Zimbabwe? Findings from a client satisfaction survey
B. Mutede, E. Tachiwenyika, R. Musarandega, B. Khabo, M. Mhangara, E. Tumbare
Zimbabwe

Congestion in urban HIV treatment clinics in Lusaka, Zambia: an assessment of factors to inform decongestion solutions
S. Moberley, A. Mwango, F. Mpsapa, H. Subramaniam, M. Prust, M. Prescott, G. Kadimba, C. Mbewe, B. Chibuye, J.W. Van den Broek, E. McCarthy
Zambia

Descriptive case study of a quality improvement intervention to implement evidence-based HIV care and improve HIV care and treatment outcomes in 17 British Columbia sites
Canada

Forecasted demand for ARV medicines in low and middle income countries up to the end of 2018
V. Habiyambere, J. Perriens, B. Dongmo-Nguimfack
WHO

The demand for CD4 testing, viral load and early infant diagnostic testing in low and middle income countries will grow strongly between now and 2018
V. Habiyambere, J. Perriens, M. Perez-Gonzales, B. Dongmo-Nguimfack, Diagnostic Access Initiative Forecasting Technical Working Group
WHO

Healthcare workers and volunteers: training, mentoring, retaining, task shifting, safety
Community Lay Cadres’ contributions and over task-shifting in expansion of antiretroviral therapy to rural health centres in Zambia
K. Komada, M. Chirwa, C. Msiska, V. Chipeta, K. Chibwe, P. Nambara, P. Mwaba, N. Kayama, C. Duba, A. Mwango
Zambia

Reductions in annual ART costs in Uganda: implications for future ART resource needs and task-shifting
Uganda

The effectiveness of men who have sex with men (MSM) sensitivity training for Nigerian health care providers (HCPs)
Nigeria

HIV training program is effective to increase HIV knowledge among health care workers in Georgia
Georgia

Taking lessons learned in the implementation of a clinical mentorship program to increase the confidence of nurses to initiate ART, in support of the roll out of Option B+
T. Moga, T. Nkomanzu, B. Mutede, T. Nyamundaya, E. Tumbare
Zimbabwe

Cryptococcal antigen screening by lay cadres using a rapid test at the point of care: a feasibility study in rural Leshoto
K. Luzinda, V. Buard, I. Damiani, S. Sedlimaier Ouattara, M. Kuleile, T. Mots'oane, M. Leqheka, G. Van Cutsen, A. Shroufi
South Africa

Demand generation for HIV services
Overcoming burden of seasonality in scaling up voluntary medical male circumcision: a case study from Tanzania
Tanzania, United Republic of

Implementing access to care interventions: structural, organizational and personnel barriers and facilitators
S. Kinsky, C. Maulsby, K. Jain, V. Charles, H. Riordan, S. Friedman
United States
TUPED781 Peer navigation in South Africa: addressing stigma and psychosocial barriers to engagement in HIV services
United States

TUPED782 Implementation of a rapid referral pathway to HIV treatment for gay men and MSM diagnosed with acute HIV-infection in sexual health clinics in British Columbia
M. Thumath, D. Moore, M. Hull, B. Brownrigg, I. Sandstra, G. Ogilvie
Canada

TUPED783 Factors associated with ART initiation among HIV-infected participants in the Bangkok men who have sex with men cohort study, 2006-2014
Thailand

TUPED785 Factors associated with disclosure of HIV status following testing HIV-positive at mobile HIV counselling and testing units in South Africa
T. Mabuto, S. Charalambous, K. Fielding, G. Churchyard, M. Hlongwane, G. Kubeka, C. Hoffmann
South Africa

TUPED786 Preliminary findings from a care facilitation approach to accelerate entry into care after HIV diagnosis from mobile HIV counselling and testing units in South Africa
T. Mabuto, S. Charalambous, K. Fielding, G. Churchyard, M. Nathane-Taulela, C. Hoffmann
South Africa

TUPED787 TB/HIV Care Association's model to increase linkage to care for sex workers: a peer linked mobile service with point of care CD4 testing and STI syndromic management
H. Hauserl, A. Lambert, H. Mhlope, M. Greeves, W. Joyce, R. Ogle
South Africa

TUPED788 Delays in antiretroviral therapy initiation among HIV-positive individuals: results of a community-based positive living with HIV (POHL) study in Kathmandu, Nepal
K.C. Poudel, D.R. Buchanan, K. Poudel-Tandukar
United States

PED798- D799 Engagement of community in service delivery

TUPED789 Enhancing community engagement through involvement of community members in delivery of antiretroviral drugs (ARV) to fellow community members: TASO Rukungiri experience
B. Kitino Joseph
Uganda

PED789- D798 Operational challenges in implementing test and treat strategies

PED790 Bringing community to cure
L. Sylla, M. Louella, E. Seeblech, T. Andrus
United States

PED800 Effects of a cognitive-behavioral intervention on condom use and serostatus disclosure in Mexicans living with HIV
N.P. Caballero Suárez, E. Rodríguez Estrada, M.C. Iglesias Chiesa, J.M. Menez Díaz, A. Riveros Rosas, G. Reyes Terrán
Mexico

www.ias2015.org
<table>
<thead>
<tr>
<th>TUPE081</th>
<th>Using the new ART guidelines to overcome the challenges of paediatric and adolescent ART enrollment in resource-limited settings: The AIDS Support Organization (TASO) Gulu experience</th>
</tr>
</thead>
<tbody>
<tr>
<td>P. Notre</td>
<td>Uganda</td>
</tr>
<tr>
<td>TUPE082</td>
<td>Peer-provided HIV counselling and testing for key populations in Cambodia: lessons learnt and implications for service delivery</td>
</tr>
<tr>
<td>T. Sovannary, Y. Siyan, J. Willem van Wijngaarden, M. Srey, G. Mburu</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>PED0803</td>
<td>Integration of HIV services with other health programmes</td>
</tr>
<tr>
<td>TUPE083</td>
<td>Integration and utilization of family planning services in a HIV clinic in Nairobi, Kenya</td>
</tr>
<tr>
<td>E. Njoguna, S. Ilovi, K. Mutai, P. Njoroge, P. Muiruri, J. Kinuthia</td>
<td>Kenya</td>
</tr>
<tr>
<td>TUPE084</td>
<td>Missed opportunities to reduce the risk of cardiovascular disease amongst people living with HIV: high prevalence of untreated cardiovascular disease risk factors at an HIV clinic in South Africa</td>
</tr>
<tr>
<td>M. Rakbin, A. Mutiti, C. Chung, Y. Zhang, Y. Wei, W. El-Sadr</td>
<td>United States</td>
</tr>
<tr>
<td>TUPE085</td>
<td>Caries experience in HIV-infected, HIV-perinatally exposed but uninfected and HIV unexposed, uninfected Nigerian children: a comparative study</td>
</tr>
<tr>
<td>M. Coker, S. El-Kamary, P. Akhigbe, O. Obuekwe, E. Mongodin, M. Charurat, W. Blattner</td>
<td>United States</td>
</tr>
<tr>
<td>TUPE086</td>
<td>An unannounced standardized patient actor assessment of STI services in public health facilities in South Africa</td>
</tr>
<tr>
<td>TUPE087</td>
<td>Does the patient experience of healthcare change following the implementation of the integration of HIV care into primary health care clinics? Perspectives from patient surveys in Free State South Africa</td>
</tr>
<tr>
<td>A. Rawat, K.E. Uebel, D. Moore, L. Cingl, J. Spiegel, A. Yassi</td>
<td>Canada</td>
</tr>
<tr>
<td>TUPE088</td>
<td>Who doesn’t disclose their HIV-positive status? Patterns of disclosure and factors associated with not disclosing to a spouse or primary sexual partner among TB-HIV patients initiating antiretroviral therapy in Lesotho</td>
</tr>
<tr>
<td>TUPE089</td>
<td>Incorporating non-communicable disease screening into community-based HIV counselling and testing in Cape Town, South Africa</td>
</tr>
<tr>
<td>M. van Niekerk, H. Draper, S.-A. Meehan</td>
<td>South Africa</td>
</tr>
<tr>
<td>TUPE0810</td>
<td>Estimating the need for integrated management of hypertension and diabetes mellitus in HIV patients, Zomba District, Malawi</td>
</tr>
<tr>
<td>TUPE0811</td>
<td>Lipid abnormalities in urban and rural patients on ART in Zomba district</td>
</tr>
<tr>
<td>TUPE0812</td>
<td>The impact of integrating HIV and sexual reproductive health services on health and healthcare-seeking behavior of female entertainment workers in Cambodia</td>
</tr>
<tr>
<td>S. Yi, P. Chhouh, S. Suong, K. Thin, K. Tith, S. Toot</td>
<td>Cambodia</td>
</tr>
<tr>
<td>TUPE0813</td>
<td>A cost-finding study of cervical cancer screening methods integrated into HIV care in Nairobi, Kenya</td>
</tr>
<tr>
<td>TUPE0814</td>
<td>Integrating HIV care and treatment services within a methadone clinic in Dar es Salaam, Tanzania: a formative research study</td>
</tr>
<tr>
<td>H. Saleem, D. Mushki, J. Mbwambo, O. Chang, B.H. Lambdin</td>
<td>United States</td>
</tr>
<tr>
<td>TUPE0815</td>
<td>Early exits from the opioid substitution treatment (OST) in Ukraine: reasons and possible explanation</td>
</tr>
<tr>
<td>A. Mazhnyaya, A. Shost, S. Filippovych, Z. Islam, F.L. Altsce</td>
<td>Ukraine</td>
</tr>
<tr>
<td>TUPE0816</td>
<td>Accelerated HIV/TB service integration into primary care clinics and programmatic outcomes in rural Swaziland</td>
</tr>
<tr>
<td>TUPE0817</td>
<td>Baseline assessment on FP service utilization among eligible HIV-positive women in Amhara, Tigray, Oromia, SNNPR and Addis Ababa</td>
</tr>
<tr>
<td>N. Barea</td>
<td>Ethiopia</td>
</tr>
<tr>
<td>TUPE0818</td>
<td>The favorable value of targeting an alcohol intervention to persons living with HIV/AIDS in Kenya</td>
</tr>
<tr>
<td>J. Kessler, K. Ruggles, A. Patel, K. Nucifora, L. Li, J. Brainwaite</td>
<td>United States</td>
</tr>
<tr>
<td>TUPE0819</td>
<td>Parents’ views and acceptability of early infant male circumcision (EIMC) integrated into maternal child health (MCH) services in Iringa, Tanzania</td>
</tr>
</tbody>
</table>
| M. Amuri, G. Msemo, J. Lija, M. Plotkin, A. Christensen, R. Lemwii, D. Boyee, A. Helar, E. Mlanga, E. Njeuhmeki, H. Mahler | Tanzania, United Republic of
<table>
<thead>
<tr>
<th>Paper Number</th>
<th>Title</th>
<th>Authors</th>
<th>Country(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TUPED21</td>
<td>Patient preference and willingness-to-pay for standalone, integrative and satellite models of dispensing methadone for the treatment of opioid dependence in Vietnam</td>
<td>B.X. Tran, V.M. Nong, H.T.T. Phan, C. Latkin</td>
<td>United States</td>
</tr>
<tr>
<td>TUPED22</td>
<td>Impact of peer nutritional counseling on ART patients’ food insecurity and nutritional outcomes: a pilot study in Honduras</td>
<td>K.P. Derose, M. Felician, B. Han, K. Palar, B. Ramirez, H. Farias, H. Martinez</td>
<td>United States</td>
</tr>
<tr>
<td>TUPED23</td>
<td>Integrating HIV and reproductive health services to increase consistent condom use for HIV prevention: a multicentre, non-randomized trial</td>
<td>R. Mutemwa, S. Mayhew, C. Warren, J. Kikuvi, D. Wang, Integra Initiative Group</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>TUPED26-28</td>
<td>Integration of HIV services with other development programmes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TUPED27</td>
<td>Decriminalization and public health on the ground: measuring policing and risk environment for people who inject drugs (PWID) in Tijuana, following the Mexican “Nacornemundo” reform</td>
<td>J. Arredondo, A. Bañuelos, T. Rocha, G. Rangel, S.A. Strathdee, L. Beletsky</td>
<td>United States</td>
</tr>
<tr>
<td>PED830-32</td>
<td>Translation, incorporation and use of key IR findings into programmes and practice</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PED830-32</td>
<td>Community-owned electronic repository: improving data access and uptake to develop evidence-informed policies and programs</td>
<td>Y. Paul, M. de Bruin, S. Mcleish, M. Fitzgerald, K. Morrison</td>
<td>Jamaica</td>
</tr>
<tr>
<td>PED831</td>
<td>Overcoming barriers to opening supervised injection services in the United States</td>
<td>L. Thomas</td>
<td>United States</td>
</tr>
<tr>
<td>PED832</td>
<td>Monitoring and evaluation of prevention programmes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PED833</td>
<td>Process evaluation of behavioural change communication materials developed and utilized for HIV prevention by non-governmental organizations in Oyo State, Nigeria</td>
<td>B. Kazeem Kolawole</td>
<td>Nigeria</td>
</tr>
<tr>
<td>PED834</td>
<td>Preliminary reliability and validity results for measures of intergenerational disjunctures that may reflect pathways between social structural change and HIV outbreaks</td>
<td>E. Pouget, M. Sandoval, Y. Jones, G. Nikolopoulos, S. Friedman</td>
<td>United States</td>
</tr>
<tr>
<td>PED835</td>
<td>Improved HIV testing uptake, food security and reduced violence among orphans and vulnerable children in Zambia: the impact of using baseline data to define program scope</td>
<td>J. Chapman, M. Nguza, Z. Charieva, J. Simbaya, J. Kamwanga, W. Kaira</td>
<td>United States</td>
</tr>
<tr>
<td>PED836</td>
<td>Households that choose to participate in community savings groups are better off than households that do not: findings from an evaluation in Zambia and implications for programming</td>
<td>J. Chapman, R. Mswi, Z. Charieva, M. Kanema, M. Nguza, J. Chege, P. Funjika, J. Kamwanga</td>
<td>United States</td>
</tr>
</tbody>
</table>

www.ias2015.org